SCHEMBL6740157

SCHEMBL6740157

CN(C#N)C(=O)[C@H](CS(=O)(=O)Cc1ccccc1OC(F)F)NC(=O)c1cccs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 7/20 0.46
CTSB P07858 6/20 0.46
CTSL P07711 2/20 0.41
CTSK P43235 2/20 0.39
CTSF Q9UBX1 2/20 0.39
HPGD P15428 3/20 0.38
MEN1 O00255 1/20 0.35
KLK7 P49862 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 2/20 0.34
RAB9A P51151 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
APLNR P35414 1/20 0.33
PTBP1 P26599 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSPA5 P11021 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6742272 0.87 CTSB (0.38) CTSSCTSBCTSLCTSKCTSF
SCHEMBL6740880 0.87 CTSB (0.38) CTSSCTSBCTSLCTSKCTSF
SCHEMBL1990970 0.87 CTSB (0.38) CTSSCTSBCTSLCTSKCTSF
SCHEMBL7658551 0.87 CTSL (0.52) CTSSCTSBCTSLCTSKCTSF
SCHEMBL6063383 0.87 CTSB (0.38) CTSSCTSBCTSLCTSKCTSF
SCHEMBL6741637 0.86 CTSS (0.42) CTSSCTSBCTSLCTSKCTSF
SCHEMBL7547881 0.86 CTSB (0.41) CTSSCTSBCTSLCTSKCTSF
SCHEMBL6063030 0.85 CTSB (0.45) CTSSCTSBCTSLCTSKCTSF
SCHEMBL1556740 0.85 CTSS (0.65) CTSSCTSBCTSLCTSKCTSF
SCHEMBL1556742 0.85 CTSS (0.65) CTSSCTSBCTSLCTSKCTSF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US claimed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US claimed
WO-2001019808-A1 CHEMICAL COMPOUNDS AND COMPOSITIONS AND THEIR USE AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-03-22 WO claimed
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US disclosed
EP-1212302-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-06-12 EP disclosed
WO-2001019808-A1 CHEMICAL COMPOUNDS AND COMPOSITIONS AND THEIR USE AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-03-22 WO disclosed
WO-2001019796-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE CTSS 1/4885CTSB 2/4885CTSL 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.